Urology
Volume 61, Issue 1 , Pages 7-9 , January 2003

What patients should be told before agreeing to a blood test that could change their lives

  • James A Talcott

      Affiliations

    • Center for Outcomes Research, MGH Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA
    • Corresponding Author InformationReprint requests: James A. Talcott, M.D., Center for Outcomes Research, Massachusetts General Hospital, E00 3C, 55 Fruit Street, Boston, MA 02114-2696, USA

Received 22 July 2002 ,Accepted 11 September 2002.

References 

  1. Tannock IF. Eradication of a disease (how we cured symptomless prostate cancer). Lancet. 2002;359:1341–1342
  2. Kramer BS, Brown ML, Prorok PC, et al.  Prostate cancer screening (what we know and what we need to know). Ann Intern Med. 1993;119:914–923
  3. Schroder FH, Boyle P. Screening for prostate cancer—necessity or nonsense?. Eur J Cancer. 1993;29A:656–661
  4. Woolf SH. Screening for prostate cancer with prostate-specific antigen (an examination of the evidence). N Engl J Med. 1995;333:1401–1405
  5. Standaert B, Denis L. The European Randomized Study of Screening for Prostate Cancer (an update). Cancer. 1997;80:1830–1834
  6. Kramer BS, Gohagan J, Prorok PC, et al.  A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. Cance. 1993;71(2 suppl):589–593
  7. Catalona WJ, Smith DS, Ratliff TL, et al.  Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993;270:948–954
  8. Bartsch G, Horninger W, Klocker H, et al.  Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology. 2001;58:417–424
  9. Lu-Yao GL, Greenberg ER. Changes in prostate cancer incidence and treatment in USA. Lancet. 1994;343:251–254
  10. Lu-Yao G, Albertsen PC, Stanford JL, et al: Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 325: 740, 2002
  11. Majeed A, Babb P, Jones J, et al.  Trends in prostate cancer incidence, mortality and survival in England and Wales 1971–1998. BJU Int. 2000;85:1058–1062
  12. Oliver SE, May MT, Gunnell D. International trends in prostate-cancer mortality in the “PSA era”. Int J Cancer. 2001;92:893–898
  13. Etzioni R, Legler JM, Feuer EJ, et al: Cancer surveillance series: interpreting trends in prostate cancer—part III: quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 91: 1033–1039, 1999
  14. Labrie F, Candas B, Dupont A, et al.  Screening decreases prostate cancer death (first analysis of the 1988 Quebec prospective randomized controlled trial). Prostate. 1999;38:83–91
  15. Jacobsen SJ, Katusic SK, Bergstralh EJ, et al.  Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA. 1995;274:1445–1449
  16. Potosky AL, Miller BA, Albertsen PC, et al.  The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273:548–552
  17. Giovannucci E, Kantoff P, Spiegelman D, et al.  The “epidemic” of early prostate cancer and the medical literature (a causal association?). Prostate Cancer and Related Diseases. 1998;1:148–153
  18. Dugan JA, Bostwick DG, Myers RP, et al.  The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA. 1996;275:288–294
  19. Etzioni R, Penson DF, Legler JM, et al.  Overdiagnosis due to prostate-specific antigen screening (lessons from U.S. prostate cancer incidence trends). J Natl Cancer Inst. 2002;94:981–990
  20. Hugosson J, Aus G, Becker C, et al.  Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden. BJU Int. 2000;85:1078–1084
  21. McGregor M, Hanley JA, Boivin JF, et al.  Screening for prostate cancer (estimating the magnitude of overdetection). Can Med Assoc J. 1998;159:1368–1372
  22. Smith DS, Carvalhal GF, Mager DE, et al.  Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men. J Urol. 1998;160:1734–1738
  23. Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol. 1997;157:199–202
  24. Fink KG, Hutarew G, Lumper W, et al.  Prostate cancer detection with two sets of ten-core compared with two sets of sextant biopsies. Urology. 2001;58:735–739
  25. Emiliozzi P, Longhi S, Scarpone P, et al.  The value of a single biopsy with 12 transperineal cores for detecting prostate cancer in patients with elevated prostate specific antigen. J Urol. 2001;166:845–850

PII: S0090-4295(02)02148-9

Urology
Volume 61, Issue 1 , Pages 7-9 , January 2003

Article Tools